Ignite Creation Date:
2025-12-24 @ 1:19 PM
Ignite Modification Date:
2025-12-29 @ 12:46 PM
Study NCT ID:
NCT04672395
Status:
COMPLETED
Last Update Posted:
2023-06-29
First Post:
2020-12-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
Sponsor:
Clover Biopharmaceuticals AUS Pty
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-24
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-04-23
Completion Date Type:
ACTUAL
First Submit Date:
2020-12-16
First Submit QC Date:
None
Study First Post Date:
2020-12-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-28
Last Update Post Date:
2023-06-29
Last Update Post Date Type:
ACTUAL